Get the Stockscreener App
14.04
0.07%
-0.01
After Hours:
14.04
Lyell Immunopharma Inc stock is traded at $14.04, with a volume of 213.76K.
It is down -0.07% in the last 24 hours and up +17.29% over the past month.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
See More
Previous Close:
$14.05
Open:
$14.11
24h Volume:
213.76K
Relative Volume:
1.62
Market Cap:
$327.61M
Revenue:
$31,000
Net Income/Loss:
$-246.41M
P/E Ratio:
-1.1022
EPS:
-12.7377
Net Cash Flow:
$-134.42M
1W Performance:
+10.12%
1M Performance:
+17.29%
6M Performance:
-45.43%
1Y Performance:
+44.89%
1-Day Range:
$13.74
$14.70
1-Week Range:
$12.41
$14.70
52-Week Range:
$9.025
$45.00
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Name
Lyell Immunopharma Inc
Sector
Industry
Phone
650 695-0677
Address
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare LYEL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
14.04 | 327.84M | 31,000 | -246.41M | -134.42M | -12.74 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Needham | Buy |
| Mar-09-26 | Initiated | Citizens | Mkt Outperform |
| Dec-09-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-30-24 | Downgrade | BofA Securities | Buy → Underperform |
| Jun-27-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-11-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-17-22 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | BofA Securities | Buy |
| Jul-12-21 | Initiated | Goldman | Buy |
| Jul-12-21 | Initiated | JP Morgan | Overweight |
| Jul-12-21 | Initiated | Morgan Stanley | Overweight |
View All
Lyell Immunopharma Inc Stock (LYEL) Latest News
Form 4 Lyell Immunopharma Inc For: 1 July By Investing.com - Investing.com Canada
Innovative Cellular Therapeutics moves 76K Lyell (LYEL) shares as broker commission - Stock Titan
Lyell Immunopharma stock maintained at Market Outperform by Citizens - Investing.com Canada
Lyell Immunopharma, Inc.(NasdaqGS: LYEL) added to Russell 2000 Index - marketscreener.com
Lyell Immunopharma, Inc.(NasdaqGS: LYEL) added to Russell 2000 Value Benchmark - marketscreener.com
Lyell Immunopharma, Inc.(NasdaqGS:LYEL) added to Russell Microcap Value Benchmark Index - marketscreener.com
Lyell Immunopharma, Inc.(NasdaqGS: LYEL) added to Russell Microcap Index - marketscreener.com
Lyell Immunopharma, Inc.(NasdaqGS: LYEL) added to Russell 3000E Value Benchmark - marketscreener.com
Lyell Immunopharma, Inc. Actuals & Estimates (NASDAQ:LYEL) - TradingView
LYEL Forecast — Price Target — Prediction for 2027 - TradingView
Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - Moomoo
LYEL Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Form 4 Lyell Immunopharma Inc For: 24 June By Investing.com - Investing.com Nigeria
Lyell Immunopharma Inc (LYEL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lyell Immunopharma (LYEL) major holder transfers shares as commission - Stock Titan
Innovative Cellular Therapeutics (LYEL) crosses 12.3% ownership after milestone - Stock Titan
Innovative Cellular Therapeutics (LYEL partner) reports 3M Lyell Immunopharma shares - Stock Titan
Lyell Immunopharma | 4: Statement of changes in beneficial ownership of securities-10% Owner Innovative Cellular Therapeutics Holdings Ltdmoomoo - Moomoo
Lyell Immunopharma issues colorectal cancer drug safety update - MSN
Lyell Immunopharma Inc (LYEL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lyell Immunopharma Inc (LYEL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lyell Immunopharma Inc (LYEL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lyell Immunopharma Inc (LYEL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lyell Immunopharma Inc (LYEL) Institutional Confidence - TradingKey
Lyell Immunopharma Inc (LYEL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lyell Immunopharma Inc (LYEL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lyell Immunopharma Inc (LYEL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lyell Immunopharma CSO Gary K. Lee sells $2,459 in LYEL stock - Investing.com Nigeria
Lyell Immunopharma CSO Gary K. Lee sells $2,459 in LYEL stock By Investing.com - Investing.com South Africa
Lyell Immunopharma COO Stephen Hill sells $1,683 in shares By Investing.com - Investing.com India
Lyell Immunopharma president and CEO Lynn Seely sells $7,337 in stock - Investing.com UK
Lyell Immunopharma COO Stephen Hill sells $1,683 in shares - Investing.com UK
Lyell Immunopharma (LYEL) CEO’s 388-share tax-related stock sale detailed in Form 4 - Stock Titan
Lyell Immunopharma (LYEL) CSO reports small tax-driven sale of company shares - Stock Titan
Lyell Immunopharma (LYEL) COO’s 89-share sale tied to RSU tax withholding - Stock Titan
Lyell Immunopharma (LYEL) VP auto-sells shares to cover RSU tax withholding - Stock Titan
Lyell Immunopharma Shareholders Back Governance at 2026 Meeting - TipRanks
Lyell Immunopharma (NASDAQ: LYEL) reports 2026 shareholder meeting and director elections - Stock Titan
Citizens upgrades Lyell Immunopharma stock price target on trial progress By Investing.com - Investing.com Canada
Lyell Immunopharma: Undervalued Ahead Of A Major CAR-T Inflection (NASDAQ:LYEL) - Seeking Alpha
Director at Lyell Immunopharma (LYEL) receives new option grant - Stock Titan
[Form 4] Lyell Immunopharma, Inc. Insider Trading Activity - Stock Titan
Lyell Immunopharma (LYEL) director awarded 9,250 stock options at $13.22 - Stock Titan
Lyell Immunopharma (LYEL) director granted 9,250 stock options at $13.22 - Stock Titan
Lyell Immunopharma (LYEL) director receives 9,250-share option grant - Stock Titan
Lyell Immunopharma (LYEL) director receives 9,250 options at $13.22 strike - Stock Titan
Lyell Immunopharma (LYEL) director receives option grant for 9,250 shares at $13.22 - Stock Titan
Lyell reports safety data for ronde-cel in lymphoma trial By Investing.com - Investing.com Canada
Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma - TradingView
New Safety Data and Translational Findings for Ronde-cel in Relapsed or Refractory Large B-Cell Lymphoma Announced by Lyell Immunopharma - Quiver Quantitative
Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress - The Manila Times
Lyell Immunopharma Inc Stock (LYEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lyell Immunopharma Inc Stock (LYEL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lee Gary K. | Chief Scientific Officer |
May 11 '26 |
Sale |
18.92 |
130 |
2,460 |
17,808 |
| Hill Stephen J. | Chief Operating Officer |
May 11 '26 |
Sale |
18.92 |
89 |
1,684 |
17,894 |
| Bulis Veronica Sanchez | VP, Corporate Controller |
May 11 '26 |
Sale |
18.91 |
217 |
4,103 |
15,420 |
| Shook David | Chief Medical Officer |
Jun 10 '26 |
Sale |
12.64 |
1,977 |
24,989 |
20,923 |
| ARCH Venture Partners IX, LLC | 10% Owner |
Mar 06 '26 |
Buy |
25.61 |
488,090 |
12,499,985 |
1,426,528 |
| ARCH Venture Fund XIII, L.P. | 10% Owner |
Mar 06 '26 |
Buy |
25.61 |
488,090 |
12,499,985 |
1,426,528 |
| Seely Lynn | President and CEO |
Feb 11 '26 |
Sale |
23.39 |
7,455 |
174,372 |
74,266 |
| Hill Stephen J. | Chief Operating Officer |
Feb 11 '26 |
Sale |
23.39 |
1,236 |
28,910 |
17,795 |
| Lee Gary K. | Chief Scientific Officer |
Feb 11 '26 |
Sale |
23.39 |
1,671 |
39,085 |
16,938 |
| Hill Stephen J. | Chief Operating Officer |
Feb 10 '26 |
Sale |
23.12 |
109 |
2,520 |
19,031 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):